PMID- 30925534
OWN - NLM
STAT- MEDLINE
DCOM- 20200416
LR  - 20200501
IS  - 1746-6318 (Electronic)
IS  - 1746-630X (Print)
IS  - 1746-630X (Linking)
VI  - 14
IP  - 3
DP  - 2019 May
TI  - Clinical and evolutionary consequences of HIV adaptation to HLA: implications for 
      vaccine and cure.
PG  - 194-204
LID - 10.1097/COH.0000000000000541 [doi]
AB  - PURPOSE OF REVIEW: The purpose of this review is to summarize recent advances in 
      our understanding of HIV adaptation to human leukocyte antigen (HLA)-associated 
      immune pressures and its relevance to HIV prevention and cure research. RECENT 
      FINDINGS: Recent research has confirmed that HLA is a major driver of individual 
      and population-level HIV evolution, that HIV strains are adapting to the 
      immunogenetic profiles of the different human ethnic groups in which they 
      circulate, and that HIV adaptation has substantial clinical and immunologic 
      consequences. As such, adaptation represents a major challenge to HIV prevention 
      and cure. At the same time, there are opportunities: Studies of HIV adaptation 
      are revealing why certain HLA alleles are protective in some populations and not 
      others; they are identifying immunogenic viral epitopes that harbor high 
      mutational barriers to escape, and they may help illuminate novel, 
      vaccine-relevant HIV epitopes in regions where circulating adaptation is 
      extensive. Elucidation of HLA-driven adapted and nonadapted viral forms in 
      different human populations and HIV subtypes also renders 'personalized' 
      immunogen selection, as a component of HIV cure strategies, conceptually 
      feasible. SUMMARY: Though adaptation represents a major challenge to HIV 
      prevention and cure, achieving an in-depth understanding of this phenomenon can 
      help move the design of such strategies forward.
FAU - Avila-Rios, Santiago
AU  - Avila-Rios S
AD  - Centre for Research in Infectious Diseases, National Institute of Respiratory 
      Diseases, Mexico City, Mexico.
FAU - Carlson, Jonathan M
AU  - Carlson JM
AD  - Microsoft Research, Seattle, Washington, USA.
FAU - John, Mina
AU  - John M
AD  - Institute for Immunology and Infectious Diseases, Murdoch University, Perth, 
      Western Australia, Australia.
FAU - Mallal, Simon
AU  - Mallal S
AD  - Institute for Immunology and Infectious Diseases, Murdoch University, Perth, 
      Western Australia, Australia.
AD  - Center for Translational Immunology and Infectious Diseases, Vanderbilt 
      University Medical Center, Nashville, Tennessee, USA.
FAU - Brumme, Zabrina L
AU  - Brumme ZL
AD  - Faculty of Health Sciences, Simon Fraser University, Burnaby.
AD  - British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, 
      Canada.
LA  - eng
GR  - P30 AI110527/AI/NIAID NIH HHS/United States
GR  - UM1 AI126617/AI/NIAID NIH HHS/United States
GR  - PJT-148621/CIHR/Canada
GR  - PJT-159625/CIHR/Canada
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Curr Opin HIV AIDS
JT  - Current opinion in HIV and AIDS
JID - 101264945
RN  - 0 (AIDS Vaccines)
RN  - 0 (HLA Antigens)
SB  - IM
MH  - AIDS Vaccines/genetics/*immunology
MH  - Adaptation, Physiological
MH  - Animals
MH  - HIV Infections/genetics/*immunology/therapy/virology
MH  - HIV-1/genetics/immunology/*physiology
MH  - HLA Antigens/genetics/*immunology
MH  - Humans
MH  - Immune Evasion
PMC - PMC6457261
MID - NIHMS1524535
COIS- Conflicts of interest The authors have no conflicts of interest to declare.
EDAT- 2019/03/30 06:00
MHDA- 2020/04/17 06:00
PMCR- 2020/05/01
CRDT- 2019/03/30 06:00
PHST- 2019/03/30 06:00 [pubmed]
PHST- 2020/04/17 06:00 [medline]
PHST- 2019/03/30 06:00 [entrez]
PHST- 2020/05/01 00:00 [pmc-release]
AID - 10.1097/COH.0000000000000541 [doi]
PST - ppublish
SO  - Curr Opin HIV AIDS. 2019 May;14(3):194-204. doi: 10.1097/COH.0000000000000541.